Discover
LXEO
Lexeo Therapeutics, Inc. Common Stock
4.66
1 x 4.44
1 x 5.69
bid
ask
+
0.11
2.42%
1 @ 04:00 PM
4.62 -0.04 (0.86%)
| Ytd | -53.07% | |
| 1y | 19.79% |
4.56
day range
4.72
3.60
52 week range
10.99
| Open | 4.61 | Prev Close | 4.55 | Low | 4.56 | High | 4.72 | Mkt Cap | 365.91M |
| Vol | 325.68K | Avg Vol | 819.85K | EPS | -1.45 | P/E | -3.21 | Forward P/E | -2.24 |
| Beta | 1.42 | Short Ratio | 6.55 | Inst. Own | 91.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 4.85 | 200-d Avg | 7.06 | 1yr Est | 22.29 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.65 | -0.89 | -0.24 | -36.92% |
| 2024-05-09 | 2024-03 | -0.76 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.76 | -0.77 | -0.01 | -1.32% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-13 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-11-13 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2024-10-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-30 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-10-25 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-01 | ADLER ERIC | Officer | 26.88K | Stock Award(Grant) |
| 2024-11-24 | CHOLMONDELEY PAULA H. J. | Director | 30.63K | Purchase |
| 2023-11-06 | LONGITUDE CAPITAL PARTNERS IV, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-11-06 | LUNDBECKFOND INVEST AS | Beneficial Owner of more than 10% of a Class of Security | 1.84M | Purchase |
| 2023-11-06 | MCCORMAC PAUL | Chief Technology Officer | 17.35K | Conversion of Exercise of derivative security |
| 2023-11-06 | OMEGA FUND VI, L.P | Beneficial Owner of more than 10% of a Class of Security | 2.16M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Janus Henderson Group PLC | 3.76M | 23.37M | 11.38% |
| 2024-09-29 | Citadel Advisors Llc | 2.72M | 16.91M | 8.24% |
| 2024-09-29 | Adage Capital Partners GP L.L.C. | 2.60M | 16.13M | 7.86% |
| 2024-09-29 | D1 Capital Partners, LP | 2.51M | 15.57M | 7.58% |
| 2024-09-29 | Omega Fund Management, Llc | 2.36M | 14.63M | 7.12% |
| 2024-09-29 | Eventide Asset Management LLC | 1.86M | 11.53M | 5.61% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 1.53M | 9.47M | 4.61% |
| 2024-09-29 | Janus Henderson Global Life Sciences Fund | 731.18K | 4.54M | 2.21% |
| 2024-10-30 | iShares Russell 2000 ETF | 595.88K | 3.70M | 1.80% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 404.87K | 2.51M | 1.22% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 272.70K | 1.69M | 0.82% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 194.83K | 1.21M | 0.59% |